Literature DB >> 10088543

Clinical significance of follicular lymphoma with monocytoid B cells. Non-Hodgkin's Lymphoma Classification Project.

B N Nathwani1, J R Anderson, J O Armitage, F Cavalli, J Diebold, M R Drachenberg, N L Harris, K A MacLennan, H K Müller-Hermelink, F A Ullrich, D D Weisenburger.   

Abstract

Although follicular lymphoma (FL) is very common in the Western world, very little information is available regarding the frequency and significance of monocytoid B cells (MBC) in FL. We recently completed a clinicopathologic study of 1,378 cases of non-Hodgkin's lymphoma. In this study, a research data sheet was designed to conduct research on several types of lymphomas, one part of which was evaluating the presence of intrafollicular clear cells and extrafollicular MBC in 326 cases diagnosed as FL by one of the pathologists (B.N.N.). For each case diagnosed as FL, the presence of intrafollicular clear cells or extrafollicular MBC was scored as pure FL (no intrafollicular clear cells or extrafollicular MBC), FL with intrafollicular clear cells, FL with less than 5% MBC, and FL with greater than 5% MBC. Of 326 cases classified as FL, 252 (77%) had no intrafollicular clear cells or extrafollicular MBC and therefore were called pure FL. In 36 cases (11%), intrafollicular clear cells were seen, but no extrafollicular MBC. There were no clinical differences between such cases and the 252 cases of pure FL. In eight cases of FL (2%), MBC clusters were rare (<5%). In contrast, 30 cases of FL (9%) had a prominent (>5%) proliferation of extrafollicular MBC; these 30 cases had a significantly shorter failure-free survival (P = .001) and overall survival (P = .04) than the 252 cases of pure FL. The shorter survival of these 30 cases appeared to be independent of the international prognostic index (IPI), stage, and treatment. The FFS of this group remained shorter than that of cases with pure FL when the analysis was restricted to patients treated with Adriamycin-containing regimens and either a favorable (0 to 3) IPI score (P = .001) or advanced stage (III/IV) disease (P = .015). In conclusion, FL with a prominent (>5%) MBC component constitutes a substantial proportion (9%) of FL and has distinctive morphology, and these patients have a significantly shorter survival than those with pure FL.

Entities:  

Mesh:

Year:  1999        PMID: 10088543     DOI: 10.1016/s0046-8177(99)90003-5

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  7 in total

Review 1.  Clinical and molecular prognostic factors in follicular lymphoma.

Authors:  Andrew J Davies
Journal:  Curr Oncol Rep       Date:  2006-09       Impact factor: 5.075

Review 2.  [Nodular lymphocyte-predominant Hodgkin's lymphoma and differential diagnoses].

Authors:  S Hartmann; S Cogliatti; M-L Hansmann
Journal:  Pathologe       Date:  2013-05       Impact factor: 1.011

3.  Disparity between the macroglobulin-producing components of 2 cases of follicular lymphoma with Waldenström's macroglobulinemia.

Authors:  Y Kuriyama; Y Uchida; M Yaguchi; A Iwabuchi; H Serizawa; J H Ohyashiki; K Ohyashiki
Journal:  Int J Hematol       Date:  2001-08       Impact factor: 2.490

4.  Pediatric nodal marginal zone lymphoma may develop in the adult population.

Authors:  Elena Gitelson; Tahseen Al-Saleem; Valentin Robu; Michael M Millenson; Mitchell R Smith
Journal:  Leuk Lymphoma       Date:  2010-01

5.  Marginal zone B-cell lymphoma in children and young adults.

Authors:  Lekidelu Taddesse-Heath; Stefania Pittaluga; Lynn Sorbara; Mary Bussey; Mark Raffeld; Elaine S Jaffe
Journal:  Am J Surg Pathol       Date:  2003-04       Impact factor: 6.394

6.  Histopathologic, immunophenotypic, and mutational landscape of follicular lymphomas with plasmacytic differentiation.

Authors:  Sarah E Gibson; Yen-Chun Liu; Svetlana A Yatsenko; Nicholas J Barasch; Steven H Swerdlow
Journal:  Mod Pathol       Date:  2021-10-02       Impact factor: 7.842

7.  Non-Hodgkin lymphoma with t(14;18): clonal evolution patterns and cytogenetic-pathologic-clinical correlations.

Authors:  Hege Vangstein Aamot; Emina Emilia Torlakovic; Marianne Brodtkorb Eide; Harald Holte; Sverre Heim
Journal:  J Cancer Res Clin Oncol       Date:  2007-01-18       Impact factor: 4.322

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.